4,6-二氯-5-氰基皮考啉酸 | 861545-83-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4,6-二氯-5-氰基皮考啉酸
• 英文名称: 4,6-Dichloro-5-cyanopicolinic acid
• 英文别名: 4,6-dichloro-5-cyanopyridine-2-carboxylic acid
• CAS: 861545-83-7
• 化学式: C₇H₂Cl₂N₂O₂
• mdl: MFCD24485714
• 分子量: 217.01
• InChiKey: NOLRVNOZBGZFCN-UHFFFAOYSA-N

物化性质

• 熔点：
  180 °C
• 沸点：
  425.2±45.0 °C(Predicted)
• 密度：
  1.71±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] 2-QUINOLONE DERIVED INHIBITORS OF BCL6<br/>[FR] INHIBITEURS DE BCL6 DÉRIVÉS DE 2-QUINOLONE
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2018215798A1

  公开（公告）日：2018-11-29

  The present invention relates to compounds of formula I that function as inhibitors of BCL6(B- cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer,as well as other diseases or conditions in which BCL6 activity is implicated.

  本发明涉及作为BCL6（B细胞淋巴瘤6）活性抑制剂的I式化合物：式中X1、X2、X3、R1、R2、R3、R4和R5分别如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增生性疾病（如癌症）以及其他BCL6活性所涉及的疾病或病况中的用途。
• [EN] BCL6 INHIBITORS<br/>[FR] INHIBITEURS DE BCL6
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2019197842A1

  公开（公告）日：2019-10-17

  The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity Formula (I) wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

  本发明涉及具有以下公式I的化合物，这些化合物作为BCL6（B细胞淋巴瘤6）活性的抑制剂发挥作用。其中X1, X2, R1, R2, R30, R31和环A均按本发明定义。本发明还涉及制备这些化合物的方法，包含它们的药物组合物，以及它们在治疗增殖性疾病，如癌症，以及BCL6活性涉及的其他疾病或状况中的应用。
• [EN] BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6<br/>[FR] INHIBITEURS DE BCL6 DÉRIVÉS DE BENZIMIDAZOLONE
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2018215801A1

  公开（公告）日：2018-11-29

  The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

  本发明涉及作为BCL6（B细胞淋巴瘤6）活性抑制剂的Formula I化合物：其中X1、X2、R1、R2和R3如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增生性疾病（如癌症）以及BCL6活性有所涉及的其他疾病或病况中的用途。
• 2-quinolone derived inhibitors of BCL6
  申请人：Cancer Research Technology Limited

  公开号：US11161839B2

  公开（公告）日：2021-11-02

  The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

  本发明涉及作为 BCL6（B 细胞淋巴瘤 6）活性抑制剂的式 I 化合物： 式 I 其中 X1、X2、X3、R1、R2、R3、R4 和 R5 各如本文所定义。 本发明还涉及这些化合物的制备工艺、包含这些化合物的药物组合物，以及它们在治疗增殖性疾病（如癌症）和其他涉及 BCL6 活性的疾病或病症中的用途。
• 2-QUINOLONE DERIVED INHIBITORS OF BCL6
  申请人：Cancer Research Technology Limited

  公开号：EP3630749A1

  公开（公告）日：2020-04-08